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Triple Drug Therapy—What
Is Next?
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The translation of clinical trial data to patient care has been a
continuing problem in patient care research. The full integra-
tion of data developed from randomized clinical trials (RCT)
in regard to angiotensin-converting enzyme (ACE) inhibitors
has lagged far behind the reports of their benefit in the
treatment of heart failure. Data collected from thousands of
patients clearly indicate that ACE inhibitors decrease the
morbidity and mortality in patients who experience symptom-
atic left ventricular dysfunction. As a result, ACE inhibitors,
although not used as widely as appropriate, have become the
foundation of heart failure therapy in patients with left ven-
tricular systolic dysfunction. In contrast, digitalis has been the
only therapeutic modality available for the treatment of heart
failure for over 200 years, and yet it too has not been
universally accepted, in part due to its presumed cardiac
arrhythmogenicity. The observations in this study support the
symptomatic benefits that can be achieved when the inotropic
effects of digoxin are added to the vasodilator effects of ACE
inhibitors, notwithstanding their effect on the renin angioten-
sin system. Unfortunately, the issues as proposed by the
authors are not quite that simple. Questions still remain as
regards our precise goals for therapy of heart failure and how
they can best be measured in lieu of a body count. What do we
know about the dose of the drugs in regard to their benefits
and their adverse effects?
The RCT in heart failure initially focused on mortality as
the measurable end point. More recently clinical efficacy has
been expanded to measurements of quality of life and of
morbidity events, such as need for hospitalization. Some
investigators have in fact suggested that improvement in
quality of life could be an acceptable positive outcome even in
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the presence of increased mortality; a pyrrhic therapeutic
victory at best. The results of RCT have in general demon-
strated a close relationship between a morbidity and mortality
benefit of ACE inhibitors, indicating a consistency of these two
endpoints (1). In contrast, the only randomized trial examining
the morbidity and mortality benefits of digoxin, conducted by
the Digitalis Investigation Group (DIG) (2), observed an
overall decrease in morbidity but no effect on mortality.
Similarly, RADIANCE (3) and PROVED (4) both indicate
that maintenance of digoxin therapy in the presence of ACE
inhibitors or diuretic is associated with a morbidity benefit. The
observations in this analysis are also compatible with the first
comparison of digoxin with the ACE inhibitor captopril during
short-term, 6 months of therapy (5). That study indicated that
digoxin was associated with an increase in ejection fraction and
captopril was associated with an increase in exercise perfor-
mance, while both digoxin and captopril decreased morbidity
(measured as need for hospitalization or emergency room
visits) when compared to diuretics alone. The fact that digoxin
had little effect on survival in DIG may be explained by its
failure to prevent remodeling. In postmyocardial infarction
patients with decreased left ventricular systolic function, im-
provement in mortality and morbidity was closely related to
the modulation of ventricular remodeling regardless of
whether the patients received ACE inhibitors (6). However,
remodeling was attenuated to a greater degree with ACE
inhibitors than with placebo. These clinical observations are
consistent with data from an animal model of heart failure in
which chronic monotherapy with digoxin improved left ventric-
ular ejection fraction but had no effect on remodeling (7). This
is in sharp contrast to the effects of monotherapy with ACE
inhibitors, which tended to prevent or attenuate remodeling in
both animal models and humans. Therefore, the positive
inotropic action of digoxin coupled with the attenuation of
remodeling observed with ACE inhibitors represents not only
a theoretic interaction but one that has a clear physiologic
effect on left ventricular dysfunction in both humans and
animal models.
What do we know about doses of either of these agents? In
both RADIANCE (3) and PROVED (4), the dose of digoxin
was closely controlled base on serum digoxin levels. The mean
digoxin dose was 0.39 mg/day and corresponded to a serum
digoxin concentration of 1.1 ng/ml when measured 24 h after
the dose; these are levels which exceed usual clinical levels. A
substudy (8) of RADIANCE (3) examined the dose response
of digoxin and observed a direct linear relationship between
dose and serum levels of digoxin on both resting and exercise
left ventricular ejection fraction. Previous animal studies indi-
cated that a linear increase occurs in contractility up to a point
at which ventricular rhythm disturbances can be induced (9). It
is possible that the increase in the arrhythmic deaths in DIG
could be an expression of digoxin toxicity, particularly in those
individuals who had renal disease. Whether there was such a
dose-related increase in mortality was apparently not exam-
ined in that study (2). It is quite likely, however, that a linear
increase in the positive inotropic effect of digoxin also occurs in
humans. A recent study suggested that there was a benefit
associated with an increased dose of ACE inhibitors, but this
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study was less than satisfactory due to a variety of design
features. Nevertheless, a case can be made for increasing the
dose of ACE inhibitors to achieve maximal blood pressure
effect. Whether further therapeutic benefit can be achieved at
higher doses with a greater modification of tissue ACE inhib-
itors is still uncertain. A more intriguing question has been
raised with the observation that physiologic escape from ACE
inhibitors may occur after 1 year of therapy (10). It was
observed that attenuation of remodeling was limited to the first
year of ACE inhibitor treatment, and after 1 year, in spite of
continued ACE inhibitor therapy, remodeling resumed and
was correlated with increased adverse events. It is well known
that with ACE inhibitors plasma angiotensin II levels remain
elevated in heart failure despite long-term therapy. Several
studies suggest that alternative pathways, independent of ACE
inhibitors exist for the production of angiotensin II within the
myocardium which have chymase-like activity (11). The exis-
tence of this metabolic pathway has added impetus to the
development and testing of angiotensin II receptor antagonists
for the treatment of heart failure.
Having accepted the concept of triple drug therapy, the
question arises as to how we can introduce new therapy. In
spite of the major improvement in the morbidity and mortality
with ACE inhibitors, heart failure mortality remains high and
its incidence is increasing in both the Western world and in the
third world as populations age. There remains a continuing
need for better drug therapy. Will we be faced with quadruple
or quintuple drug therapy? If this is the case, not only will
compliance be difficult and expensive, but significant interac-
tion can and will occur. We already have on the horizon the
potential for quadruple drug therapy with the reported mor-
tality benefits of beta-adrenergic blocking agents, metoprolol
(12), carvedilol (13) and most recently bisoprolol (Dargie HJ,
personal communication, 1998). At the same time the poten-
tial benefit of angiotensin II receptor blockers is being studied
as both unique therapy and in combination with ACE inhibi-
tors. In addition to these drugs there are a number of new
potential agents under investigation, including aldosterone
receptor blockers, T type calcium-channel blockers, dopamine
beta hydroxylase inhibitors, endothelin receptor blockers and
growth hormones agents, to name but a few. How will we be
able to conduct clinical trials without obfuscating the investi-
gations with multiple drugs as baseline therapy? Although
patients consent, Institutional Review Boards and national
regulatory bodies have demanded that contemporary effective
therapy be provided to patients as new drugs are tested; the
reality is that many patients are not taking ACE inhibitors even
though they have been shown to be beneficial. Yet most of the
current drug exploration does include triple drug therapy at
baseline. These studies presume that there is no drug interac-
tion with the drug being studied. However, if current studies
are shown to be successful, baseline therapy by necessity may
include quadruple or quintuple drugs. The possibility is more
than an illusion. With this potential, one should keep in mind
the fact that even though ACE inhibitors have been studied in
almost 100,000 patients, clinicians are not convinced entirely of
their benefit since their clinical use still falls far short of their
potential application. A major issue for the future is how we
can gain sufficient information from future studies to achieve
physician acceptance. At the present time, this analysis of
RADIANCE (3) and PROVED (4) supports the use of triple
drug therapy in patients with symptomatic left ventricular
failure. How we will accommodate future drugs remains a
major problem.
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